Catalym Gmbh

This study is testing whether adding a new antibody drug called visugromab to standard immunotherapy helps shrink bladder tumors before surgery. It's for patients with muscle-invasive bladder cancer who cannot receive or refuse standard cisplatin chemotherapy. The goal is to see …

This trial is testing a new drug called CTL-002 (visugromab) for adults with advanced solid tumors that have returned or stopped responding to standard treatments, including immunotherapy. The study has two parts: first finding a safe dose, then testing that dose in combination w…